APA (7th ed.) Citation

Ji, D., Luo, Y., Wang, J., Chen, S., Lan, B., Ma, F., . . . Fan, Y. (2023). CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: A network meta-analysis. BMC.

Chicago Style (17th ed.) Citation

Ji, Danyang, Yang Luo, Jiayu Wang, Shanshan Chen, Bo Lan, Fei Ma, Binghe Xu, and Ying Fan. CDK4/6 Inhibitors, PI3K/mTOR Inhibitors, and HDAC Inhibitors as Second-line Treatments for Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: A Network Meta-analysis. BMC, 2023.

MLA (9th ed.) Citation

Ji, Danyang, et al. CDK4/6 Inhibitors, PI3K/mTOR Inhibitors, and HDAC Inhibitors as Second-line Treatments for Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: A Network Meta-analysis. BMC, 2023.